Karyopharm Therapeutics (KPTI) Non Operating Interest Expenses (2015 - 2026)

Karyopharm Therapeutics (KPTI) has reported Non Operating Interest Expenses for 9 consecutive years, with $13.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Interest Expenses rose 17.06% year-over-year to $13.1 million; the trailing twelve-month figure through Jun 2026 stood at $48.0 million (up 7.11% YoY), and the FY2025 full-year result was $45.8 million, up 22.52% from the prior year.
• Non Operating Interest Expenses climbed to $13.1 million in Q2 2026 per KPTI's latest filing, from $12.6 million in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $13.1 million in Q2 2026 and bottomed at $5.8 million in Q1 2023.
• Historically, Non Operating Interest Expenses has averaged $8.5 million across 5 years, with a median of $6.7 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Non Operating Interest Expenses fell 25.88% in 2022, then soared 87.47% in 2024.
• Over 5 years, Non Operating Interest Expenses stood at $5.9 million in 2022, then grew by 5.49% to $6.2 million in 2023, then soared by 80.48% to $11.2 million in 2024, then increased by 12.63% to $12.6 million in 2025, then advanced by 4.16% to $13.1 million in 2026.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $13.1 million, $12.6 million, and $11.0 million for Q2 2026, Q4 2025, and Q3 2025 respectively.